Commentary Open Access
Cancer of Unknown Primary Site in the Era of Molecular Diagnosis, Staging and Precision Therapy: A Commentary
F. Anthony Greco1,*
- 1Tennessee Oncology, Greco-Hainsworth Centers for Research, Sarah Cannon Cancer Center Nashville, Tennessee, USA
Corresponding Author
F. Anthony Greco, fgreco@tnonc.com
Received Date: May 12, 2026
Accepted Date: June 12, 2026
Greco FA. Cancer of Unknown Primary Site in the Era of Molecular Diagnosis, Staging and Precision Therapy: A Commentary. J Cancer Immunol. 2026;8(2):47–55.
Copyright: © 2026 Greco FA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Impact of Cisplatin Dosing Regimens on Mammary Tumor Growth in an Animal Model
In a recent paper, we introduced a variant of the classical Simeoni tumor growth model, and illustrated its value in assessing tumor growth in a reproducible mouse model for mammary tumors. Our modification consisted of incorporating delay differential equations in the mathematical formulation of the Simeoni model, to represent the delay in drug action often observed under chemotherapeutic or immunotherapeutic regimens.
The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors
Glucocorticoids (GCs) are defined by their role in maintaining glucose homeostasis and natural GCs are a class of corticosteroids secreted by the adrenal cortex. Cortisol is the most important natural GC in humans. Cellular cortisol levels are regulated by the tissue-specific metabolic enzymes 11β-hydroxysteroid dehydrogenase 1 and 2 (11β-HSD 1 and 2); 11β-HSD 1 converts inactive cortisone to active cortisol, while 11β-HSD 2 has the opposite function.
Can Filtration Technology Advance Culture of Circulating Tumor Cells towards Precision Medicine?
Expansion of Circulating Tumor Cells (CTC), the metastatic seeds of cancer in the blood stream, holds great potential in clinical application, especially towards precision medicine. Given the relatively rare nature of CTCs, their culture remains to be a significant challenge. When developing technologies for CTC culture, there are key elements that need careful consideration, including the speed of culture, compatibility with downstream analysis, and the implementation of the technology into established clinical daily routines. Herein, we briefly discuss the implications of our recent report of an ultrathin filter for the capture and culture of circulating colon cancer cells.
Influence of Clinical Risk Factors on Outcomes in Men with Stage I Non-Seminomatous Germ Cell Tumor Undergoing Robot-Assisted Retroperitoneal Lymph Node Dissection
We recently published our multi-institutional experience performing primary robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for men with non-seminomatous germ cell tumor (NSGCT). We concluded that primary RA-RPLND for NSGCT can be performed safely with low complication rates, acceptable early oncologic outcomes, and lower overall theoretical chemotherapy burden. In this commentary, we explore outcomes in clinical stage I patients stratified by clinical risk factors (RF) and estimate reductions in chemotherapy burden.
Leucocyte-Tumor Cell Hybridization Can Initiate Cancer Metastasis
According to estimates from the International Agency for Research on Cancer, by the year 2030 there will be 22 million new cancer cases and 13 million deaths per year. The main reason for death from cancer is not the initial tumor but it’s metastasis to distant parts of the body, yet this process has remained poorly understood for quite some time.